Case Report: Variable Pharmacokinetic Profile of Eculizumab in an aHUS Patient

BACKGROUND: With the introduction of eculizumab, a C5-inhibitor, morbidity and mortality improved significantly for patients with atypical hemolytic uremic syndrome (aHUS). In view of the high costs, actual needs of the drug, and increasing evidence in literature, aHUS patients can be treated accord...

Descripción completa

Detalles Bibliográficos
Autores principales: Bouwmeester, Romy N., Ter Avest, Mendy, Wijnsma, Kioa L., Duineveld, Caroline, ter Heine, Rob, Volokhina, Elena B., Van Den Heuvel, Lambertus P. W. J., Wetzels, Jack F. M., van de Kar, Nicole C. A. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843372/
https://www.ncbi.nlm.nih.gov/pubmed/33519821
http://dx.doi.org/10.3389/fimmu.2020.612706

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843372/
https://www.ncbi.nlm.nih.gov/pubmed/33519821
http://dx.doi.org/10.3389/fimmu.2020.612706

Ejemplares similares